DK1171123T3 - Fremgangsmåde til behandling af nervecelledöd - Google Patents

Fremgangsmåde til behandling af nervecelledöd

Info

Publication number
DK1171123T3
DK1171123T3 DK01906242T DK01906242T DK1171123T3 DK 1171123 T3 DK1171123 T3 DK 1171123T3 DK 01906242 T DK01906242 T DK 01906242T DK 01906242 T DK01906242 T DK 01906242T DK 1171123 T3 DK1171123 T3 DK 1171123T3
Authority
DK
Denmark
Prior art keywords
cell death
nerve cell
treating nerve
treating
death
Prior art date
Application number
DK01906242T
Other languages
Danish (da)
English (en)
Inventor
Eiichi Otomo
Y Takasu
Original Assignee
Hamilton Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamilton Pharmaceuticals Inc filed Critical Hamilton Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1171123T3 publication Critical patent/DK1171123T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK01906242T 2000-02-23 2001-02-23 Fremgangsmåde til behandling af nervecelledöd DK1171123T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51195200A 2000-02-23 2000-02-23

Publications (1)

Publication Number Publication Date
DK1171123T3 true DK1171123T3 (da) 2006-12-04

Family

ID=24037094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01906242T DK1171123T3 (da) 2000-02-23 2001-02-23 Fremgangsmåde til behandling af nervecelledöd

Country Status (20)

Country Link
US (2) US6423739B1 (enExample)
EP (1) EP1171123B1 (enExample)
JP (1) JP2003523385A (enExample)
KR (1) KR20010110798A (enExample)
CN (1) CN1362877A (enExample)
AR (1) AR030551A1 (enExample)
AT (1) ATE336246T1 (enExample)
AU (1) AU784418B2 (enExample)
BR (1) BR0104586A (enExample)
CA (1) CA2368352C (enExample)
DE (1) DE60122252T2 (enExample)
DK (1) DK1171123T3 (enExample)
ES (1) ES2270981T3 (enExample)
HK (1) HK1047038A1 (enExample)
ID (1) ID30377A (enExample)
IL (1) IL145799A (enExample)
MX (1) MXPA01010749A (enExample)
NO (1) NO321911B1 (enExample)
TW (1) TWI289060B (enExample)
WO (1) WO2001062246A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
CN1484527A (zh) * 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
US20040192759A1 (en) * 2001-08-22 2004-09-30 Eiichi Otomo Use of nefiracetam for treating neurodegeneration
RU2205631C1 (ru) * 2002-06-19 2003-06-10 Закрытое акционерное общество "Брынцалов-А" Ноотропное средство "ноотобрил" в форме таблеток
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
ES2664727T3 (es) 2009-10-22 2018-04-23 University College Dublin National University Of Ireland, Dublin Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469995A (en) * 1946-07-23 1949-05-10 Schaul Martin Carl Process for the production of food preparations from potatoes and similar farinaceoustubers
US3031314A (en) * 1960-03-16 1962-04-24 Carl E Hendel Preparation of dehydrated potatoes
US3260607A (en) * 1961-02-07 1966-07-12 Canadian Patents Dev Preparation of dehydrated cooked mashed potato
US3968265A (en) * 1973-02-01 1976-07-06 American Potato Company Freeze-thaw stable, french fry potato product and process for producing the same
DE2924011C2 (de) 1979-06-13 1982-04-08 A. Nattermann & Cie GmbH, 5000 Köln Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten
DE2923975A1 (de) 1979-06-13 1980-12-18 Nattermann A & Cie Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel
IT1141287B (it) 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
SK279285B6 (sk) 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5525058A (en) 1992-03-27 1996-06-11 American Dental Technologies, Inc. Dental treatment system
KR100232929B1 (ko) 1995-07-10 1999-12-01 히로지 코데라 가공 선재의 접속 장치
US6107330A (en) 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
ES2185963T3 (es) 1996-07-30 2003-05-01 Ecolab Gmbh & Co Ohg Agente filmogeno para la proteccion contra infecciones.
EP0953356A4 (en) 1996-10-01 2002-04-17 Daiichi Seiyaku Co MITOCHONDRIAL MEMBRANE STABILIZER
US6211701B1 (en) 1996-12-16 2001-04-03 Rose Research, Llc Low power line switching circuit, device and method
IT1293533B1 (it) 1997-07-14 1999-03-01 Angeletti P Ist Richerche Bio Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che
AU8131198A (en) 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
AR020115A1 (es) 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
KR20020015321A (ko) 1999-05-31 2002-02-27 스즈키 다다시 신경 세포사 억제제

Also Published As

Publication number Publication date
US20020055534A1 (en) 2002-05-09
IL145799A (en) 2006-10-31
AU3414501A (en) 2001-09-03
ES2270981T3 (es) 2007-04-16
BR0104586A (pt) 2002-01-08
ID30377A (id) 2001-11-29
IL145799A0 (en) 2002-07-25
WO2001062246A1 (en) 2001-08-30
KR20010110798A (ko) 2001-12-13
AU784418B2 (en) 2006-03-30
NO20015162L (no) 2001-12-21
AR030551A1 (es) 2003-08-27
DE60122252T2 (de) 2007-07-05
US6399650B2 (en) 2002-06-04
CN1362877A (zh) 2002-08-07
NO321911B1 (no) 2006-07-17
DE60122252D1 (de) 2006-09-28
JP2003523385A (ja) 2003-08-05
EP1171123A1 (en) 2002-01-16
US6423739B1 (en) 2002-07-23
HK1047038A1 (zh) 2003-02-07
CA2368352A1 (en) 2001-08-30
ATE336246T1 (de) 2006-09-15
TWI289060B (en) 2007-11-01
CA2368352C (en) 2009-11-10
NO20015162D0 (no) 2001-10-22
MXPA01010749A (es) 2002-08-20
EP1171123B1 (en) 2006-08-16
US20010051653A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
DK1249151T3 (da) Fremgangsmåde til cellegenvalgssignalering
DK1132569T3 (da) Fremgangsmåde til behandling af en underjordisk formation
DK3167872T3 (da) Fremgangsmåder til behandling af inflammationsmedierede tilstande i øjet
NO20030241D0 (no) Fremgangsmåte for behandling av multiple brönnintervaller
DK1121192T3 (da) Fremgangsmåde til homogenisering
DK2283867T3 (da) Fremgangsmåder til behandling ved anvendelse af anti-ErbB antistof-maytansinoidkonjugater
DK1390014T3 (da) Sammensætning til anvendelse i en fremgangsmåde til behandling af hyperplasi
DE60044004D1 (de) Verwendung von Omega-Carboxyaryl-substituierten Diphenylharnstoffen als raf-Kinase-Inhibitoren
DE60124301D1 (de) Dünnschichtelektroden zum feststellen von herzdepolarisationsignalen
EE200300088A (et) Imidasolo-5-üül-2-anilino-pürimidiinid raku proliferatsiooni inhibitsiooni agensitena
DK1132570T3 (da) Sammensætninger til syrebehandling af borebrönde
ID25682A (id) Metode untuk melelehkan kaca
DK1091086T3 (da) Vandige gelerede sammensætninger til behandling af borebrönde
IS6521A (is) Aðferð til að hreinsa gerjunarseyði
NO20005318D0 (no) FremgangsmÕter og anordninger ved behandling av vann
DK1414492T3 (da) Fremgangsmåde til behandling af multipel myeloma
DE60128788D1 (de) Zusammensetzung und verfahren zur bekämpfung von pflanzenschädlichen arthropoden
DK1539200T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1314824T3 (da) Fremgangsmåde til konsolidering af jord
DK1461047T3 (da) Sammensætninger og fremgangsmåde til behandling af dyr
IS5742A (is) Aðferð til genalækninga
DK1294659T3 (da) Fremgangsmåde til isolering af katamin
DK1702623T3 (da) Anvendelse af interferon-gamma til behandling af hjertehypertrofi
DK1105136T3 (da) Fremgangsmåde til behandling af okulære neovaskulære sygdomme